Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Terminated 1Recruiting 1

Sponsor Class

OTHER 6INDUSTRY 5NIH 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 1Melanoma 1

Interventions

pembrolizumab 279Carboplatin 214Cisplatin 145Gemcitabine 144Paclitaxel 142Bevacizumab 115Pemetrexed 112Docetaxel 100Oxaliplatin 78Dexamethasone 77durvalumab 76Fluorouracil 76atezolizumab 75Nivolumab 74Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 68Cetuximab 63Capecitabine 63Injections 61Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 49venetoclax 43Prednisone 43Irinotecan 42enzalutamide 39Letrozole 39tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × cobimetinib × 90 days × Clear all
NCT03178552 2026-06-05

B-FAST

Hoffmann-La Roche

Phase 2/3 Active not recruiting
1,000 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04302025 2026-05-22

NAUTIKA1

Genentech, Inc.

Phase 2 Recruiting
99 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03337698 2026-05-12

Morpheus Lung

Hoffmann-La Roche

Phase 1/2 Terminated
314 enrolled 31 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03768063 2026-04-28

IMbrella B

Hoffmann-La Roche

Phase 3 Active not recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

NCT04835805 2026-03-30

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Genentech, Inc.

Phase 1 Active not recruiting
65 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡